Skip to Main Content

Paper Details

Prognostic Mutations in Myelodysplastic Syndrome after Stem-Cell Transplantation.
New England Journal of Medicine
483
2017
JAK2, JAK2 mutations, MDS, Myelodysplastic Syndrome, PPM1D, RAS, RAS pathway, SBDS, SBDS gene, Shwachman-Diamond syndrome, Stem-Cell, TP53, TP53 mutations, hematopoietic stem-cell, myelodysplastic syndrome, p53, p53 regulator PPM1D, patients
Author NameAffiliation
Robert Coleman LindsleyDana-Farber Cancer Institute, Brigham and Women's Hospital, Harvard Medical School (P.V.G., B.L.E.) - all in Boston the Center for International Blood and Marrow Transplant Research, Medical College of Wisconsin, S.J.L.) the Center for International Blood and Marrow Transplant Research, University of Minnesota (M.R.V.) - both in Minneapolis the Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle (S.J.L.) Memorial Sloan Kettering Cancer Center, New York (K.H.) and the Institute for Experimental Cellular Therapy, University Hospital Essen
Brenton G MarDana-Farber Cancer Institute, Brigham and Women's Hospital, Harvard Medical School (P.V.G., B.L.E.) - all in Boston the Center for International Blood and Marrow Transplant Research, Medical College of Wisconsin, S.J.L.) the Center for International Blood and Marrow Transplant Research, University of Minnesota (M.R.V.) - both in Minneapolis the Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle (S.J.L.) Memorial Sloan Kettering Cancer Center, New York (K.H.) and the Institute for Experimental Cellular Therapy, University Hospital Essen
Peter V GraumanDana-Farber Cancer Institute, Brigham and Women's Hospital, Harvard Medical School (P.V.G., B.L.E.) - all in Boston the Center for International Blood and Marrow Transplant Research, Medical College of Wisconsin, S.J.L.) the Center for International Blood and Marrow Transplant Research, University of Minnesota (M.R.V.) - both in Minneapolis the Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle (S.J.L.) Memorial Sloan Kettering Cancer Center, New York (K.H.) and the Institute for Experimental Cellular Therapy, University Hospital Essen
Donna NeubergDana-Farber Cancer Institute, Brigham and Women's Hospital, Harvard Medical School (P.V.G., B.L.E.) - all in Boston the Center for International Blood and Marrow Transplant Research, Medical College of Wisconsin, S.J.L.) the Center for International Blood and Marrow Transplant Research, University of Minnesota (M.R.V.) - both in Minneapolis the Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle (S.J.L.) Memorial Sloan Kettering Cancer Center, New York (K.H.) and the Institute for Experimental Cellular Therapy, University Hospital Essen
Benjamin L EbertDana-Farber Cancer Institute, Brigham and Women's Hospital, Harvard Medical School (P.V.G., B.L.E.) - all in Boston the Center for International Blood and Marrow Transplant Research, Medical College of Wisconsin, S.J.L.) the Center for International Blood and Marrow Transplant Research, University of Minnesota (M.R.V.) - both in Minneapolis the Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle (S.J.L.) Memorial Sloan Kettering Cancer Center, New York (K.H.) and the Institute for Experimental Cellular Therapy, University Hospital Essen
  • 1 - 5

Datasets